Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies.
Fairfoul G., McGuire LI., Pal S., Ironside JW., Neumann J., Christie S., Joachim C., Esiri M., Evetts SG., Rolinski M., Baig F., Ruffmann C., Wade-Martins R., Hu MTM., Parkkinen L., Green AJE.
We have developed a novel real-time quaking-induced conversion RT-QuIC-based assay to detect alpha-synuclein aggregation in brain and cerebrospinal fluid from dementia with Lewy bodies and Parkinson's disease patients. This assay can detect alpha-synuclein aggregation in Dementia with Lewy bodies and Parkinson's disease cerebrospinal fluid with sensitivities of 92% and 95%, respectively, and with an overall specificity of 100% when compared to Alzheimer and control cerebrospinal fluid. Patients with neuropathologically confirmed tauopathies (progressive supranuclear palsy; corticobasal degeneration) gave negative results. These results suggest that RT-QuiC analysis of cerebrospinal fluid is potentially useful for the early clinical assessment of patients with alpha-synucleinopathies.